Michael D Tennant

Title: Michael D. Tennant: Innovator in Gene Therapy

Introduction

Michael D. Tennant is a notable inventor based in Seattle, WA, who has made significant contributions to the field of gene therapy. His innovative work focuses on the adiponectin gene, which plays a crucial role in regulating glucose levels and fatty acid breakdown.

Latest Patents

Tennant holds a patent for his groundbreaking work on adiponectin gene therapy. The patent details the cloning of adiponectin cDNA into AAV serotypes 1, 2, and 5-based expression vectors. These vectors were administered to the livers of rat subjects via portal vein injection. A single injection of 6×10 virions of the vector resulted in a sustained and statistically significant reduction in body weight of the treated animals compared to control animals. This remarkable outcome occurred without any side effects. Additionally, the treated rats exhibited reduced adipose tissue mass, decreased appetite, improved insulin sensitivity, and enhanced glucose tolerance.

Career Highlights

Tennant is associated with Applied Genetic Technologies Corporation, where he continues to advance his research in gene therapy. His work has the potential to impact the treatment of metabolic disorders significantly.

Collaborations

One of his notable collaborators is Sergei Zolotukhin, with whom he has worked on various projects related to gene therapy.

Conclusion

Michael D. Tennant's innovative contributions to gene therapy, particularly in the area of adiponectin, highlight his role as a leading inventor in the field. His work promises to pave the way for new treatments for metabolic disorders, showcasing the importance of innovation in medical research.